Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer

Sushil K. Badrising; Vincent van der Noort; Paul Hamberg; Jules L. L. M. Coenen; Maureen J. Aarts; Inge M. van Oort; Alfons J. M. van den Eertwegh; Maartje Los; H. Pieter van den Berg; Hans Gelderblom; Suzan Vrijaldenhoven; Emile D. Kerver; Theo van Voorthuizen; Igle J. de Jong; John B. Haanen; Andries M. Bergman

doi:10.1159/000448219

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer

Sushil K. Badrising, Vincent van der Noort, Paul Hamberg, Jules L. L. M. Coenen, Maureen J. Aarts, Inge M. van Oort, Alfons J. M. van den Eertwegh, Maartje Los, H. Pieter van den Berg, Hans Gelderblom, Suzan Vrijaldenhoven, Emile D. Kerver, Theo van Voorthuizen, Igle J. de Jong, John B. Haanen, Andries M. Bergman^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Objective: To evaluate the efficacy of enzalutamide (Enz) as fourth- or fifth-line treatment in men with metastasized castration-resistant prostate cancer (mCRPC), by analyzing a retrospective cohort of heavily pretreated patients.
Methods: We evaluated toxicity, overall survival (OS), progression-free survival (PFS) and time to prostate-specific antigen (PSA) progression data from 47 CRPC patients treated with fourth- or fifth-line Enz.
Results: All patients were treated with docetaxel and abiraterone acetate and 42 patients (89%) with cabazitaxel. The median age of the patients was 69 years (IQR, 63-73.5), 79% had bone metastases, 55% had lymph node metastases, and 17% had visceral metastases. The median duration of Enz treatment was 12.0 weeks (IQR, 8.3-20.4), and 11 patients (23%) responded to Enz (maximum PSA decline ≥50%). In general, Enz was well tolerated, with the most frequently reported adverse events being fatigue and nausea. The median OS was 40.1 weeks (95% CI, 25.4-61.4), the median PFS was 12.1 weeks (95% CI, 9.9-14.0) and the median time to PSA progression was 15.7 weeks (95% CI, 14.0-28.7).
Conclusions: Analysis of this retrospective cohort suggests that Enz is well tolerated and that there is a 23% response rate in heavily pretreated CRPC patients, which is comparable with third-line treatment outcomes.

Original language	English
Pages (from-to)	267-273
Number of pages	7
Journal	Oncology
Volume	91
Issue number	5
DOIs	https://doi.org/10.1159/000448219
Publication status	Published - 2016

Keywords

Cross-resistance
Treatment sequence
Heavily pretreated patients
Time interval
Docetaxel
Abiraterone
Cabazitaxel
Radium-223

Access to Document

10.1159/000448219

Cite this

Badrising, S. K., van der Noort, V., Hamberg, P., Coenen, J. L. L. M., Aarts, M. J., van Oort, I. M., van den Eertwegh, A. J. M., Los, M., van den Berg, H. P., Gelderblom, H., Vrijaldenhoven, S., Kerver, E. D., van Voorthuizen, T., de Jong, I. J., Haanen, J. B., & Bergman, A. M. (2016). Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer. Oncology, 91(5), 267-273. https://doi.org/10.1159/000448219

@article{22e02f650b5446dc88e8cff83d1d9730,

title = "Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer",

abstract = "Objective: To evaluate the efficacy of enzalutamide (Enz) as fourth- or fifth-line treatment in men with metastasized castration-resistant prostate cancer (mCRPC), by analyzing a retrospective cohort of heavily pretreated patients. Methods: We evaluated toxicity, overall survival (OS), progression-free survival (PFS) and time to prostate-specific antigen (PSA) progression data from 47 CRPC patients treated with fourth- or fifth-line Enz. Results: All patients were treated with docetaxel and abiraterone acetate and 42 patients (89%) with cabazitaxel. The median age of the patients was 69 years (IQR, 63-73.5), 79% had bone metastases, 55% had lymph node metastases, and 17% had visceral metastases. The median duration of Enz treatment was 12.0 weeks (IQR, 8.3-20.4), and 11 patients (23%) responded to Enz (maximum PSA decline ≥50%). In general, Enz was well tolerated, with the most frequently reported adverse events being fatigue and nausea. The median OS was 40.1 weeks (95% CI, 25.4-61.4), the median PFS was 12.1 weeks (95% CI, 9.9-14.0) and the median time to PSA progression was 15.7 weeks (95% CI, 14.0-28.7). Conclusions: Analysis of this retrospective cohort suggests that Enz is well tolerated and that there is a 23% response rate in heavily pretreated CRPC patients, which is comparable with third-line treatment outcomes.",

keywords = "Cross-resistance, Treatment sequence, Heavily pretreated patients, Time interval, Docetaxel, Abiraterone, Cabazitaxel, Radium-223",

author = "Badrising, {Sushil K.} and {van der Noort}, Vincent and Paul Hamberg and Coenen, {Jules L. L. M.} and Aarts, {Maureen J.} and {van Oort}, {Inge M.} and {van den Eertwegh}, {Alfons J. M.} and Maartje Los and {van den Berg}, {H. Pieter} and Hans Gelderblom and Suzan Vrijaldenhoven and Kerver, {Emile D.} and {van Voorthuizen}, Theo and {de Jong}, {Igle J.} and Haanen, {John B.} and Bergman, {Andries M.}",

year = "2016",

doi = "10.1159/000448219",

language = "English",

volume = "91",

pages = "267--273",

journal = "Oncology",

issn = "0030-2414",

publisher = "Karger",

number = "5",

}

Badrising, SK, van der Noort, V, Hamberg, P, Coenen, JLLM, Aarts, MJ, van Oort, IM, van den Eertwegh, AJM, Los, M, van den Berg, HP, Gelderblom, H, Vrijaldenhoven, S, Kerver, ED, van Voorthuizen, T, de Jong, IJ, Haanen, JB & Bergman, AM 2016, 'Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer', Oncology, vol. 91, no. 5, pp. 267-273. https://doi.org/10.1159/000448219

TY - JOUR

T1 - Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer

AU - Badrising, Sushil K.

AU - van der Noort, Vincent

AU - Hamberg, Paul

AU - Coenen, Jules L. L. M.

AU - Aarts, Maureen J.

AU - van Oort, Inge M.

AU - van den Eertwegh, Alfons J. M.

AU - Los, Maartje

AU - van den Berg, H. Pieter

AU - Gelderblom, Hans

AU - Vrijaldenhoven, Suzan

AU - Kerver, Emile D.

AU - van Voorthuizen, Theo

AU - de Jong, Igle J.

AU - Haanen, John B.

AU - Bergman, Andries M.

PY - 2016

Y1 - 2016

N2 - Objective: To evaluate the efficacy of enzalutamide (Enz) as fourth- or fifth-line treatment in men with metastasized castration-resistant prostate cancer (mCRPC), by analyzing a retrospective cohort of heavily pretreated patients. Methods: We evaluated toxicity, overall survival (OS), progression-free survival (PFS) and time to prostate-specific antigen (PSA) progression data from 47 CRPC patients treated with fourth- or fifth-line Enz. Results: All patients were treated with docetaxel and abiraterone acetate and 42 patients (89%) with cabazitaxel. The median age of the patients was 69 years (IQR, 63-73.5), 79% had bone metastases, 55% had lymph node metastases, and 17% had visceral metastases. The median duration of Enz treatment was 12.0 weeks (IQR, 8.3-20.4), and 11 patients (23%) responded to Enz (maximum PSA decline ≥50%). In general, Enz was well tolerated, with the most frequently reported adverse events being fatigue and nausea. The median OS was 40.1 weeks (95% CI, 25.4-61.4), the median PFS was 12.1 weeks (95% CI, 9.9-14.0) and the median time to PSA progression was 15.7 weeks (95% CI, 14.0-28.7). Conclusions: Analysis of this retrospective cohort suggests that Enz is well tolerated and that there is a 23% response rate in heavily pretreated CRPC patients, which is comparable with third-line treatment outcomes.

AB - Objective: To evaluate the efficacy of enzalutamide (Enz) as fourth- or fifth-line treatment in men with metastasized castration-resistant prostate cancer (mCRPC), by analyzing a retrospective cohort of heavily pretreated patients. Methods: We evaluated toxicity, overall survival (OS), progression-free survival (PFS) and time to prostate-specific antigen (PSA) progression data from 47 CRPC patients treated with fourth- or fifth-line Enz. Results: All patients were treated with docetaxel and abiraterone acetate and 42 patients (89%) with cabazitaxel. The median age of the patients was 69 years (IQR, 63-73.5), 79% had bone metastases, 55% had lymph node metastases, and 17% had visceral metastases. The median duration of Enz treatment was 12.0 weeks (IQR, 8.3-20.4), and 11 patients (23%) responded to Enz (maximum PSA decline ≥50%). In general, Enz was well tolerated, with the most frequently reported adverse events being fatigue and nausea. The median OS was 40.1 weeks (95% CI, 25.4-61.4), the median PFS was 12.1 weeks (95% CI, 9.9-14.0) and the median time to PSA progression was 15.7 weeks (95% CI, 14.0-28.7). Conclusions: Analysis of this retrospective cohort suggests that Enz is well tolerated and that there is a 23% response rate in heavily pretreated CRPC patients, which is comparable with third-line treatment outcomes.

KW - Cross-resistance

KW - Treatment sequence

KW - Heavily pretreated patients

KW - Time interval

KW - Docetaxel

KW - Abiraterone

KW - Cabazitaxel

KW - Radium-223

U2 - 10.1159/000448219

DO - 10.1159/000448219

M3 - Article

C2 - 27544669

SN - 0030-2414

VL - 91

SP - 267

EP - 273

JO - Oncology

JF - Oncology

IS - 5

ER -